Business
Passage Bio to Participate in Upcoming Investor Conferences
PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced management will participate in the following upcoming investor conferences: TD Cowen 45th Annual Health Care ConferenceFormat: Management will participate in a presentation and investor meetingsDate: Wednesday, March 5, 2025Presentation Time: 9:10 a.m. ETLocation: Boston, MA Leerink
About this update from Passage Bio, Inc.
PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced management will participate in the following upcoming investor conferences: TD Cowen 45 th Annual Health Care Conference Format: Management will participate in a presentation and investor meetings Date: Wednesday, March 5, 2025 Presentation Time: 9:10 a.m. ET Location: Boston, MA Leerink Global Biopharma Conference Format: Management will participate in a presentation and investor meetings Date: Wednesday, March 12, 2025 Presentation Time: 8:00 a.m. ET Location: Miami, FL A live webcast of the event will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com . A replay of the presentation will be available for 30 days following the event. About Passage Bio Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio’s lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression. To learn more about Passage Bio and our steadfast commitment to protecting patients and families against loss in neurodegenerative conditions, please visit: passagebio.com . For further information, please contact: Investors: Stuart Henderson Passage Bio [email protected] Passage Bio Media: Mike Beyer Sam Brown Inc. Healthcare Communications 312.961.2502 [email protected]